RT Journal Article
SR Electronic
T1 Passive and active immunity in infants born to mothers with SARS-CoV-2 infection during pregnancy: Prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.01.21255871
DO 10.1101/2021.05.01.21255871
A1 Song, Dongli
A1 Prahl, Mary
A1 Gaw, Stephanie L.
A1 Narasimhan, SudhaRani
A1 Rai, Daljeet
A1 Huang, Angela
A1 Flores, Claudia
A1 Lin, Christine Y.
A1 Jigmeddagva, Unurzul
A1 Wu, Alan H.B.
A1 Warrier, Lakshmi
A1 Levan, Justine
A1 Nguyen, Catherine B.T.
A1 Callaway, Perri
A1 Farrington, Lila
A1 Acevedo, Gonzalo R.
A1 Gonzalez, Veronica J.
A1 Vaaben, Anna
A1 Nguyen, Phuong
A1 Atmosfera, Elda
A1 Marleau, Constance
A1 Anderson, Christina
A1 Misra, Sonya
A1 Stemmle, Monica
A1 Cortes, Maria
A1 McAuley, Jennifer
A1 Metz, Nicole
A1 Patel, Rupalee
A1 Nudelman, Matthew
A1 Abraham, Susan
A1 Byrne, James
A1 Jegatheesan, Priya
YR 2021
UL http://medrxiv.org/content/early/2021/05/03/2021.05.01.21255871.abstract
AB OBJECTIVE To investigate maternal immunoglobulins’ (IgM, IgG) response to SARS-CoV-2 infection during pregnancy and IgG transplacental transfer, to characterize neonatal antibody response to SARS-CoV-2 infection, and to longitudinally follow actively- and passively-acquired SARS-CoV-2 antibodies in infants.DESIGN A prospective observational study.SETTING A public healthcare system in Santa Clara County (CA, USA).PARTICIPANTS Women with SARS-CoV-2 infection during pregnancy and their infants were enrolled between April 15, 2020 and March 31, 2021.OUTCOMES SARS-CoV-2 serology analyses in the cord and maternal blood at delivery and longitudinally in infant blood between birth and 28 weeks of life.RESULTS Of 145 mothers who tested positive for SARS-CoV-2 during pregnancy, 86 had symptomatic infections: 78 with mild-moderate symptoms, and eight with severe-critical symptoms. Of the 147 newborns, two infants showed seroconversion at two weeks of age with high levels of IgM and IgG, including one premature infant with confirmed intrapartum infection. The seropositivity rates of the mothers at delivery was 65% (95% CI 0.56-0.73) and the cord blood was 58% (95% CI 0.49-0.66). IgG levels significantly correlated between the maternal and cord blood (Rs= 0.93, p< 0.0001). IgG transplacental transfer ratio was significantly higher when the first maternal positive PCR was 60-180 days before delivery compared to <60 days (1.2 vs. 0.6, p=<0.0001). Infant IgG negative conversion rate over follow-up periods of 1-4, 5-12, and 13-28 weeks were 8% (4/48), 12% (3/25), and 38% (5/13), respectively. The IgG seropositivity in the infants was positively related to IgG levels in the cord blood and persisted up to six months of age.CONCLUSIONS Maternal SARS-CoV-2 IgG is efficiently transferred across the placenta when infections occur more than two months before delivery. Maternally-derived passive immunity may protect infants up to six months of life. Neonates mount a strong antibody response to perinatal SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis works was supported by Bill and Melinda Gates Foundation (INV-017035 to SLG), National Institutes of Health (NIAID K08AI141728 to SLG, NIAID K23AI127886 to MP), Marino Family Foundation, and Valley Medical Center Foundation. The funders did not have any role in the study design, patient recruitment, data collection, analysis, or interpretation of the results. All the authors had full access to the full data in the study and accept responsibility to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board Santa Clara Valley Medical Center.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data is published in Mendeley data sharing site and available in the following doi:10.17632/6scfwt55fd.2. http://dx.doi.org/10.17632/6scfwt55fd.2